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Background: Progressive cognitive decline develops in a nontrivial minority of stroke survivors. 
Although commonly used to identify cognitive decline in older stroke survivors, the usefulness 
of the Mini-Mental State Examination (MMSE) as a screening tool for post-stroke cognitive 
decline across a wider range of ages is not well established. This study therefore investigated 
the usefulness of the MMSE for this purpose.
Methods: Twenty-seven subjects, aged 18–82 years, with a single known remote stroke 
were assessed using the MMSE. The frequency of cognitive impairment was determined by 
comparison of MMSE scores with population-based norms. Relationships between cognitive 
performance, motor impairments, age, gender, handedness, stroke laterality, and time since 
stroke also were explored.
Results: Age-adjusted MMSE scores identified mild cognitive impairment in 22.2% and 
moderate-to-severe cognitive impairment in 7.4% of subjects. Raw and age-adjusted MMSE 
scores were inversely correlated with time since stroke, but not with other patient or stroke 
characteristics.
Conclusion: A relationship between time since single known stroke and MMSE performance 
was observed in this study. The proportion of subjects identified as cognitively impaired in this 
group by Z-transformation of MMSE scores using previously published normative data for 
this measure comports well with the rates of late post-stroke cognitive impairment reported 
by other investigators. These findings suggest that the MMSE, when normatively interpreted, 
may identify cognitive decline in the late period following single known stroke. Additionally, 
the lack of a relationship between MMSE and Fugl-Meyer scores suggests that the severity of 
post-stroke motor impairments is unlikely to serve as a clinically useful indicator of the need for 
cognitive assessment. A larger study of stroke survivors is needed to inform more fully on the 
usefulness of normatively interpreted MMSE scores as a method of screening for post-stroke 
cognitive decline.
Keywords: stroke, Mini-Mental State Examination, cognitive decline, Fugl-Meyer evaluation, 
motor impairment
Introduction
Improvement of acute stroke-induced cognitive impairments is expected over the 
months to years following stroke,1–8 with as many as 30% of stroke survivors expe-
riencing complete cognitive recovery by 18 months post-stroke.9 Among persons 
who do not experience a complete recovery from post-stroke cognitive impairments, 
conventional clinical wisdom suggests that those individuals maintain persistent but 
stable cognitive impairments thereafter. However, a nontrivial minority of stroke Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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survivors develop progressive cognitive decline over the first 
two years following a single known stroke.
For example, Ballard et al6 performed cognitive assess-
ments three and 15 months following stroke in 115 individuals 
without overt dementia in the immediate post-stroke period. 
Although 50% of these subjects demonstrated cognitive 
improvements by 15 months following stroke, 9% declined 
cognitively over that same time period. These subjects were 
without prior or subsequent known strokes, suggesting that 
even a single known stroke may provoke vascular dementia. 
Other studies offer similar evidence of cognitive decline in the 
months to years following stroke, with rates of dementia by two 
years post-stroke of 9%–31%.8–11 In these studies, extended 
periods of observation after stroke (1–2 years) revealed higher 
rates of cognitive impairment than did studies with relatively 
short post-stroke observation periods (less than one year).
Other patient or stroke characteristics may facilitate the 
identification of persons at risk for post-stroke cognitive 
decline. Advanced age appears to be a risk factor for dementia 
following stroke,8 with a one-year post-stroke prevalence of 
dementia of 7% in those aged ,65 years and 53% in those 
aged .85 years.12 Multivariate analyses of large stroke 
cohorts demonstrate associations between long-term post-
stroke cognitive impairment and educational level,13 lower 
socioeconomic status,14 ethnicity (Afro-Caribbean, Asian),14 
stroke severity,13 left hemispheric lesion,14 prior cerebrovas-
cular disease,13 dysphasia,13 visual field defect,14 and urinary 
incontinence.14 These studies suggest that some patient and/
or stroke characteristics, as well as medical comorbidities (eg, 
prior cerebrovascular disease, incontinence), may serve to 
prompt clinicians to evaluate patients with such characteristics 
for post-stroke cognitive decline.
From a practical standpoint, particularly in the busy clini-
cal practices of neurologists, physiatrists, and primary care 
physicians caring for stroke survivors, screening for post-
stroke cognitive decline presents several challenges. First, 
in a time-limited setting, it is often impractical to administer 
more than a brief measure of general cognition, such as the 
Mini-Mental State Examination (MMSE).15 Formal neu-
ropsychological testing is often useful for the identification 
and quantification of post-stroke cognitive impairments, but 
obtaining support for such testing is inconsistently available, 
especially in many managed care environments.16 As such, 
the task of assessing post-stroke cognitive performance is 
often relegated to primary care physicians, neurologists, 
psychiatrists, and physiatrists, and therefore the office-
based assessment of cognition is frequently limited to the 
MMSE.
While the MMSE is not a substitute for formal 
neuropsychological testing, it appears to be a useful mea-
sure for the assessment of post-stroke cognitive decline. For 
example, Laukka et al17 suggest that the MMSE may be a useful 
measure with which to identify forthcoming vascular dementia 
in adults $75 years of age, and Madureira et al18 found the 
MMSE to be a useful screening measure of cognition among 
older persons in the post-acute (three-month) period following 
stroke. However, the usefulness of the MMSE measure for 
the identification of post-stroke cognitive impairment across 
a broader age range and in the late (ie, more than one year) 
period following stroke has not been established.
Additionally, the types of stroke-related impairments asso-
ciated with incipient post-stroke dementia noted above (eg, 
dysphasia, visual field defect, severity of initial stroke, urinary 
incontinence) are often challenging to identify and quantify 
in a brief office visit, particularly in non-neurological clinical 
settings. When such are identified, clinicians may be more 
likely to perform cognitive screening tests, assuming that the 
presence and severity of other stroke sequelae may serve as a 
gauge of the likelihood and/or severity of post-stroke cogni-
tive impairments. However, it is possible that the relationship 
between cognitive and other stroke-related impairments may 
be an artifact of age, with older persons experiencing more 
frequent impairments in a variety of neurological and func-
tional domains, regardless of whether there are causal rela-
tionships between such impairments. Accordingly, it would 
be useful to understand more fully the relationship between 
post-stroke motor and cognitive impairments in the late period 
following stroke, and particularly whether the former serve 
as a proxy with which to identify stroke survivors in need of 
more detailed cognitive assessment.
The present study was undertaken to address these issues 
by investigating the usefulness of the MMSE as a screening 
tool for post-stroke cognitive decline among younger stroke 
survivors, and particularly the utility of interpreting MMSE 
performance according to population-based norms for this 
purpose. Additionally, relationships between cognitive per-
formance, motor performance, time since stroke, and a lim-
ited set of easily identified patient and stroke characteristics 
were investigated for the purpose of determining whether 
these variables serve usefully to identify survivors of remote 
strokes in need of cognitive assessment.
Materials and methods
This study was approved by the HealthONE Alliance Insti-
tutional Review Board, and all subjects provided informed 
consent for study participation.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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subjects
Individuals who experienced a single known stroke at least 
12 months prior to study participation were recruited nation-
ally via printed and Internet media for participation in a 
study examining the effects of constraint-induced movement 
therapy on chronic post-stroke upper extremity motor impair-
ments. Participants were enrolled on the basis of the onset 
and persistence of moderate-to-severe upper extremity motor 
impairments following a single known stroke, with moderate-
to-severe upper extremity motor impairment, defined as 
movement from a resting position limited to wrist extension 
of no more than 20°, metacarpophalangeal and interpha-
langeal joint extension of no more than 20°, but preserved 
ability to grasp a washcloth using any method of prehension. 
Subjects were also required to have the ability to sit at the 
bedside for 10 minutes without support, to follow directions 
using written, verbal, or demonstration instructions, and to 
have no other serious and/or uncontrolled medical conditions. 
  Findings from the constraint-induced movement therapy 
protocol into which these subjects subsequently entered are 
described elsewhere.19–21 Medical records were reviewed for 
the purpose of determining stroke type and laterality.
Outcome measures
Subjects completed pretreatment assessments using the 
MMSE15 and the Fugl-Meyer evaluation of physical perfor-
mance.22 The MMSE is a brief cognitive assessment measure 
used commonly by physicians and allied health care providers 
in clinical practice. MMSE scores range between 0 and 30, 
with higher scores reflecting better performance. This mea-
sure was administered and scored using the method described 
by Folstein et al.15 In order to account for the effect of age 
prior to interpreting MMSE scores, adjusted MMSE scores 
were calculated using the population-based norms reported 
by Crum et al.23 Mild cognitive impairment was defined as 
an MMSE score $1 standard deviation (SD) below age-
adjusted performance expectations,24 and moderate or greater 
cognitive impairment was defined as an MMSE score $2 SD 
below age-adjusted performance expectations.
The Fugl-Meyer assessment generated a score for upper 
extremity performance (FM-UE) based on motor skill, coor-
dination, and speed of upper extremity movement; FM-UE 
scores range from 0 to 66, with lower scores reflecting more 
severe impairment. The Fugl-Meyer assessment also gener-
ates a total motor performance score (FM-T) based on the 
FM-UE and also joint range of motion, pain, and sensory 
function, as well as lower extremity function. For the purpose 
of this study, FM-T scores ranged from 0 to 126 points, again 
with lower scores reflecting more severe impairment. All 
administrations of the Fugl-Meyer assessment were com-
pleted by one occupational therapist following Fugl-Meyer 
testing guidelines22 and employed a standardized assessment 
environment (ie, the same chair, testing equipment, and test-
ing procedures used for every subject). Determination of 
handedness was also made during the course of Fugl-Meyer 
assessment. Test-retest reliability on both the FM-UE and 
FM-T were determined by repeat assessment of 10 randomly 
selected patients; for both measures, the Pearson product 
moment correlation was r = 0.96 (P , 0.05).
statistical analyses
All statistical analyses were performed using Statistica 6.0 
(Statsoft Inc, Tulsa, OK). Pearson product moment correla-
tion coefficients were calculated for age versus MMSE (raw 
and age-adjusted), age versus Fugl-Meyer (FM-UE or FM-T), 
time since stroke versus MMSE (raw and age-adjusted), 
time since stroke versus Fugl-Meyer (FM-UE or FM-T), and 
MMSE (raw and age-adjusted) versus Fugl-Meyer (FM-UE 
or FM-T). Student t-tests were used to investigate differ-
ences in MMSE and FM-T scores as a function of gender, 
laterality of stroke, and cerebral dominance. These analyses 
were cross-validated by dividing the study group into those 
with and without cognitive impairment (ie, age-adjusted 
performance $1 SD below norm-based expectations) and 
then using Student t-tests to investigate between-group 
differences in age, time since stroke, FM-UE, and FM-T. 
χ2 analyses were used to investigate differences in gender, 
cerebral dominance, and laterality of stroke among subjects 
with and without cognitive impairment.
Results
Twenty-seven subjects (10 of whom were female) were 
included. The study group is described in Table 1 (continu-
ous variables of interest) and Table 2 (categorical variables 
of interest). Mild cognitive impairment was observed in 
6/27 subjects (22.2%), and moderate or greater cognitive 
Table 1 study group characteristics (continuous variables)
Mean (± SD) Median Range
Age (years) 58.5 ± 16.8 60.0 18–82
Time post-stroke (years) 5.9 ± 5.2 3.5 1–20
MMse 27.3 ± 3.4 28.0 14–30
Age-adjusted MMse -0.10 ± 1.6 0.4 -5.7–1.9
Fugl-Meyer (upper extremity) 30.3 ± 9.6 26.0 17–51 
Fugl-Meyer (total) 84.8 ± 11.8 84.0 66–112
Abbreviations: sD, standard deviation; MMse, Mini-Mental state examination.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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impairment was observed in 2/27 subjects (7.4%). Time 
since stroke was inversely correlated with both raw and 
age-adjusted MMSE scores (r = -0.65, P , 0.001, and 
r = -0.59, P , 0.002, respectively), but not with FM-UE 
or FM-T scores. Age was not correlated with raw or age-
adjusted MMSE scores, but age was inversely correlated 
with FM-UE and FM-T scores (both r = -0.47, P , 0.02). 
Neither raw nor age-adjusted MMSE scores correlated 
with FM-UE or FM-T scores. Relationships between age-
adjusted MMSE scores, FM-T scores, and age are presented 
in Figure 1, and relationships between age-adjusted MMSE 
scores, FM-T scores, and time since stroke are presented 
in Figure 2. Raw and age-adjusted MMSE scores did not 
differ as a function of gender, cerebral dominance, or 
laterality of stroke. Similarly, FM-UE or FM-T scores did 
not differ as a function of gender, cerebral dominance, or 
laterality of stroke.
After dividing subjects into groups with and without 
cognitive impairment, there were no significant differences 
between these groups with respect to age, gender, cerebral 
dominance, laterality of stroke, FM-UE, or FM-T scores. 
However, time since injury was significantly longer among 
subjects with MMSE-determined cognitive impairment 
(10.3 ± 8.4 years) when compared with subjects performing 
within normal limits for age on this measure (4.6 ± 3.2 years, 
t = 2.6, P , 0.02).
Discussion
The present findings suggest that the MMSE, particularly 
when interpreted using age-adjusted normative data, may be 
useful in the identification of post-stroke cognitive impair-
ment among both younger and older adult stroke survivors. 
This suggestion is consistent with the conclusions of other 
investigators25–27 and the American Heart Association.28 
Table 2 study group characteristics (categorical variables)
gender 17 men 63%
10 women 37%
handedness 23 right 85%
3 left 11%
1 mixed   4%
hemispheric laterality of stroke 15 left 56%
12 right 44%
stroke type 17 ischemic 63%
6 hemorrhagic 22%
1 mixed   4%
3 undetermined 11%
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Our findings clarify these suggestions by demonstrating 
that the usefulness of the MMSE for this purpose relies 
upon   Z-transforming scores on this measure. Age influ-
ences MMSE performance, and the magnitude of the effect 
of age on MMSE performance increases with advancing 
age. Accordingly, interpreting MMSE scores in a manner 
that adequately controls for the potential confound of age-
related performance decrements necessitates Z-transforming 
raw MMSE scores using the best available normative data.23 
In this study, age-adjusted MMSE scores identified 22.2% 
of subjects in this study with cognitive impairment of at 
least mild severity, 50% of whom were #60 years of age 
(see Figure 1). Moderate or greater cognitive impairment 
(ie, vascular dementia) was identified in 7.4% of subjects, 
consistent with frequencies identified in studies using more 
extensive neuropsychological testing batteries.8–11 By com-
parison, using raw MMSE cutoff scores of #25 or #24 
would identify only 18.5% or 7.4%, respectively, of sub-
jects in this group as cognitively impaired. The even more 
conservative cutoff score of ,20 (for “organicity”), origi-
nally proposed by Folstein et al,15 would identify only 1/27 
(3.7%) of subjects in this sample as cognitively impaired. 
Therefore, we suggest that using raw MMSE score cutoff 
values to establish cognitive impairment is not appropriate, 
and may explain why some other groups conclude (perhaps 
erroneously) that this measure underestimates the frequency 
of post-stroke cognitive decline.29–32 Conversely, applying 
a less conservative raw MMSE cutoff score of #26 to our 
sample overidentifies subjects (29.6%) as having cognitive 
impairments of at least mild severity. Collectively, these 
observations suggest that the MMSE may be useful as an 
assessment for clinically significant post-stroke cognitive 
decline, and that the interpretation of MMSE scores for this 
purpose is best undertaken by comparing individual scores 
with published normative data.23
Cognitive performance as assessed by both raw and age-
adjusted MMSE scores was inversely correlated with time 
since stroke, but was not correlated with the severity of post-
stroke motor impairments, age, gender, cerebral dominance, 
or laterality of stroke. By contrast, the severity of post-stroke 
motor impairment was correlated with age, but was not cor-
related with time since stroke or the other patient or stroke 
characteristics assessed in this study. The pattern of relation-
ships between cognitive performance, motor function, age, 
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and time since stroke observed in this study is complex. These 
relationships are considered individually and collectively in 
the service of considering their potential application to the 
care and future study of stroke survivors.
The correlation between cognitive performance and time 
since stroke suggests a time-related decline in cognition in 
the late period following stroke. Importantly, that decline is 
not accounted for by age, post-stroke motor impairment, or 
the other subject and stroke characteristics evaluated in this 
study. Although the association between increased severity 
of cognitive impairment and time since stroke observed in 
this study is likely to be multifactorial, two interpretations 
are immediately forthcoming.
First, it is possible that the cognitive performance of these 
subjects simply reflects their pre-stroke cognitive baseline, 
persistent and stable cognitive impairments since the time of 
stroke, or both, and that the apparent relationship between 
time since stroke and cognitive impairment is spurious. The 
strength of the association between time since stroke and 
both raw MMSE and age-adjusted MMSE scores suggests 
that the likelihood of a Type I error in this analysis is small, 
but this possibility cannot be dismissed entirely in light of 
the relatively small sample size of the present study.
Second, and more likely, our present findings suggest that 
a nontrivial minority of stroke survivors develop progres-
sive cognitive decline in the late post-stroke period. That 
decline may result from the cumulative effects of additional 
(including otherwise clinically “silent”) cerebrovascular 
disease,33–37 the induction of Alzheimer’s-type neuropathol-
ogy by cerebrovascular disease,38–41 or both of these and/
or other factors.42–46 This interpretation is concordant with 
findings from other similar studies,24,37,47–49 and suggests that 
a single known stroke is probably understood most usefully 
as an overt manifestation of an underlying cerebrovascular 
process that in a substantial minority of individuals will result 
in gradual cognitive decline.
In contrast with post-stroke cognitive performance, 
motor performance remained relatively more stable as a 
function of time since stroke. However, motor performance 
demonstrated a clear age-related decline. The quality of 
motor function varies with normal aging,50 and clinically 
apparent motor decline begins in the fifth decade of life. By 
contrast, the Crum et al23 data suggest that significant age-
related decline in MMSE scores is not expected until the 
eighth decade of life. These observations might suggest that 
age may more strongly influence motor performance than 
cognitive performance among relatively younger stroke 
survivors. Given that the mean age in the present study was 
58.5 ± 16.8 years, the present observation of a relationship 
between age and   post-stroke motor performance, but not 
between age and MMSE scores, is not entirely unexpected.
It is also important to note that the severity of motor 
impairments experienced by the subjects in this study were 
just short of plegia of the affected limb or hemibody. The lack 
of correlation between post-stroke cognitive performance 
and motor performance is therefore even more important to 
highlight here. If in this group there is no significant associa-
tion between motor and cognitive performance, then severity 
of motor impairments seems unlikely to serve usefully as an 
indicator of post-stroke cognitive impairments.
The present study suffers from several limitations, including 
its development as a secondary analysis of cognition in a sample 
of stroke survivors recruited for a different purpose (constraint-
induced movement therapy of post-stroke motor impairments), 
cross-sectional rather than longitudinal assessment of cognition 
and motor function, nonblinded assessments, lack of a matched 
comparison sample, lack of extensive demographic data (eg, 
educational levels, ethnicity, primary language, socioeconomic 
status), absence of overall stroke severity metrics (eg, National 
Institutes of Health Stroke Scale51), lack of ascertainment of 
potential confounds such as neuropsychiatric conditions (ie, 
depression, anxiety, substance use) and neuroactive medications 
on cognitive and motor performance, and lack of assessment 
with the formal neuropsychological testing needed to establish 
the validity of the rates of cognitive impairment identified by 
Z-transformed MMSE scores. Of particular note, the recruit-
ment strategy for the constraint-induced movement therapy 
study may at least in part contribute to the lack of correlation 
between motor and cognitive performance in the present sam-
ple. As noted earlier, subjects were required to be able to follow 
directions using written, verbal, or demonstration instructions. 
This requirement reduces the likelihood of enrolling subjects 
with functionally significant language impairments, and would 
tend to bias MMSE scores towards the less impaired range. 
Accordingly, these subjects were less likely than the general 
stroke population to demonstrate an association between motor 
and cognitive (including language) abilities. It is possible that, 
if subjects with more overt impairments of language had been 
included in the present study, a correlation between motor and 
cognitive performance might have been observed. Conversely, 
the finding of an association between time since stroke and 
cognitive performance despite the apparent selection bias 
against patients with aphasia is that much more noteworthy, 
because it suggests that post-stroke language disturbances 
alone are unlikely to explain the MMSE scores observed in 
these subjects.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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In summary, the present findings suggest that the MMSE 
may serve as a useful screening measure of post-stroke cognitive 
performance across a wide age range, particularly when MMSE 
scores are interpreted with respect to population-based norms 
rather than raw MMSE cutoff scores. Additionally, the present 
study findings suggest that clinicians should remain vigilant for 
the development of progressive cognitive decline throughout the 
post-stroke period, and that such vigilance should be maintained 
regardless of a patient’s age and/or severity of post-stroke motor 
impairments. Given the morbidity and mortality risks posed by 
post-stroke cognitive impairment52–54 and promise of emerging 
therapies for the treatment of vascular dementia,55–61 routine 
screening for cognitive impairments among stroke survivors 
is necessary if such treatments are to be offered early in the 
course of vascular dementia, when preservation of function 
may yield the greatest benefits for affected persons and their 
families. The present findings suggest that identification of cog-
nitive impairments rests upon direct assessment of cognition, 
and that recognition of other patient or stroke characteristics 
are neither suitable substitutes nor reliable prompts for post-
stroke cognitive assessment. Prospective studies are needed to 
validate the present findings, including direct comparison of 
the rates of cognitive impairment identified by Z-transformed 
MMSE scores versus formal neuropsychological testing, and 
to investigate further their clinical implications.
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